Lurasidone Generic Availability: What to Know for 2023 and Beyond
The availability of generic lurasidone hinges on patent expirations and potential legal challenges. As of late 2023 and into 2024, the landscape for generic lurasidone is shaped by these factors.
When Does Lurasidone's Key Patent Expire?
The primary patent protecting lurasidone, a medication used to treat schizophrenia and bipolar depression, was set to expire in 2027. However, a separate patent, also related to the drug, expired in 2023 [1]. The expiration of patents is a critical step towards enabling generic competition.
Have Generic Versions of Lurasidone Been Approved?
The U.S. Food and Drug Administration (FDA) has approved generic versions of lurasidone. For example, Teva Pharmaceuticals received approval for its generic lurasidone tablets in September 2023 [1]. This indicates that generic lurasidone is becoming available.
Are There Any Legal Challenges Affecting Lurasidone Patents?
Patent disputes can delay or prevent generic entry. Companies often challenge patents to accelerate the availability of their generic versions. Information regarding specific legal challenges to lurasidone patents can be tracked through specialized resources [2].
How Does Generic Availability Impact Lurasidone Pricing?
The introduction of generic drugs typically leads to a significant decrease in medication costs. Once generic lurasidone is widely available, patients and insurance providers can expect lower prices compared to the branded version, Latuda.
What is the Status of Lurasidone Exclusivity Periods?
Beyond patent expiry, other exclusivity periods can influence generic availability. For instance, the Hatch-Waxman Act provides for certain periods of market exclusivity that can prevent generic approval for a set time after the approval of a new drug [3]. The expiration of these exclusivity periods, in addition to patents, is necessary for generic market entry.
---
Sources:
[1] https://drugpatentwatch.com/drugs/lurasidone/approved-generics
[2] https://drugpatentwatch.com/drugs/lurasidone/litigation
[3] https://drugpatentwatch.com/resources/exclusivity